Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in endocrinology. Its lead product, TransCon Growth Hormone, is designed to provide a sustained release of growth hormone, setting it apart from traditional therapies. The company operates primarily in the United States and Europe, leveraging its proprietary TransCon technology platform.
Ascendis generates revenue primarily through the commercialization of its lead product, TransCon Growth Hormone, which targets growth hormone deficiency. The company benefits from high gross margins of 85.1%, indicating strong pricing power in a niche market. The unique delivery mechanism of its therapies provides a competitive advantage by improving patient compliance and outcomes.
FDA approval timelines for new therapies
Market adoption rates of TransCon Growth Hormone
Partnership developments for international expansion
Clinical trial results for pipeline products
Regulatory changes that could affect drug approval processes
Technological disruption in drug delivery mechanisms
Emergence of biosimilars for growth hormone therapies
Increased competition from other biotech firms with similar products
High debt levels could strain cash flow if revenue growth slows
Liquidity risks due to negative net income margins
low - The demand for rare disease treatments is relatively inelastic, as these therapies are often essential for patients.
Interest rates have a minimal direct impact on Ascendis, but higher rates could affect the overall biotech funding environment and investor sentiment towards growth stocks.
minimal - The company has a manageable debt-to-equity ratio of 1.84, indicating some reliance on debt, but not heavily dependent on credit markets.
growth - Investors are likely attracted to the high revenue growth potential and innovative product pipeline.
high - The stock has demonstrated significant volatility, with a 1-year return of 31.3%, indicating a high beta.
